EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn reduce NPY levels via muscarinic receptor activation

Neil R Jani, Valerie Y H van Weperen, Thamali Ayagama, Jonathan D Hoang, Maryam Emamimeybodi, Benjamin Mothibe Bussmann, Sartaj Bal, Ashna Kumar, Artin Khaky, David Hamon, Neil Herring iD, Corey Smith und 1 weitere

Cardiovascular Research · 22.11.2025 · 121 (14) · 2189-2203

DOI: 10.1093/cvr/cvaf180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 06.10.2025. Verfasst von Neil R Jani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Electrophysiology Programs, Division of Cardiology, Department of Medicine, University of California, 100 Medical Plaza, Suite 660, Los Angel…. Hauptthemen laut MEDLINE: Receptors, Neuropeptide Y, Neuropeptide Y, Vagus Nerve Stimulation, Stellate Ganglion. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Institute of Health, British Heart Foundation Senior Clinical Research Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Ventricular arrhythmias are associated with sympathoexcitation and increased co-transmitter neuropeptide Y (NPY) levels. Vagal nerve stimulation (VNS) has been reported to decrease release of norepinephrine, while NPY has been reported to decrease acetylcholine release ex vivo by binding Y2 receptors on parasympathetic nerves. We hypothesized that VNS reduces NPY levels via a muscarinic receptor (MR) mediated mechanism in vivo and that, in turn, blockade of pre-synaptic Y2R can further enhance the effects of VNS and decrease the effects of sympathoexcitation by increasing vagal tone. Methods and results Single-cell RNA sequencing of rat stellate ganglia and immunohistochemistry were performed and identified the M2 receptor as the predominant subtype on NPY-expressing sympathetic neurons. Ex vivo field stimulation of rat stellate ganglia, before and after application of carbamylcholine (CCH; muscarinic agonist) and atropine (muscarinic blocker) showed that CCH reduced NPY release, while the addition of atropine increased NPY levels. Subsequently, to validate ex vivo findings, in vivo effects of VNS during bilateral stellate ganglia stimulation (BSS) on NPY release with and without atropine were evaluated and haemodynamic and electrophysiological parameters, including ventricular activation recovery intervals (ARIs, a surrogate for action potential duration), and real-time in vivo interstitial NPY levels were measured. Post-atropine, suppression of NPY by VNS was significantly diminished, confirming a MR mediated mechanism in vivo. Finally, in a porcine model in vivo, effects of VNS on NPY levels and of the Y2R blocker, BIIE0246, during BSS were tested. These studies demonstrated that Y2R blockade significantly reduced the cardiac effects of BSS on systolic pressure, inotropy, and ARIs. While the ventricular effects of VNS, including suppression of interstitial NPY levels, haemodynamic, and electrophysiological parameters were enhanced by Y2R blockade, heart rate remained unaffected.

Conclusion

Vagal activation reduces interstitial NPY levels via a pre-synaptic sympathetic M2R mechanism. Y2R inhibition reduces effects of sympathoexcitation and enhances the effects of VNS in vivo. These findings highlight the role of NPY in sympathovagal crosstalk and suggest Y2R as a potential target to modulate autonomic balance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Neuropeptide YNeuropeptide YVagus Nerve StimulationStellate GanglionVagus NerveReceptor, Muscarinic M2Muscarinic AntagonistsArrhythmias, CardiacHeartAnimalsMaleRats, Sprague-DawleySignal TransductionHeart RateRatsDisease Models, AnimalMuscarinic AgonistsAction Potentials

Stichwörter der Autor:innen

Cardiac autonomic nervous systemMuscarinic receptorsNeuropeptide YSympatheticVagus nerve stimulationY2 receptor

Substanzen

Receptors, Neuropeptide YNeuropeptide Yneuropeptide Y2 receptorReceptor, Muscarinic M2Muscarinic AntagonistsMuscarinic Agonists

Autor:innen und Institutionen

  • Cardiac Electrophysiology Programs, Division of Cardiology, Department of Medicine, University of California, 100 Medical Plaza, Suite 660, Los Angeles, CA 90095, USA.
  • Burdon Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.
  • Division of Cardiology, Department of Medicine, University of Iowa, Iowa City, IA, USA.
  • Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, USA.

ORCID-Profile: Neil Herring, Marmar Vaseghi

Förderung

  • NHLBI NIH HHS
  • National Institute of Health
  • British Heart Foundation Senior Clinical Research Fellowship
  • British Heart Foundation Clinical Research Fellowship
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Jani, N. R., van Weperen, V. Y. H., Ayagama, T., Hoang, J. D., Emamimeybodi, M., Bussmann, B. M., Bal, S., Kumar, A., Khaky, A., Hamon, D., Herring, N., Smith, C., & Vaseghi, M. (2025). Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn reduce NPY levels via muscarinic receptor activation. Cardiovascular Research, 121(14), 2189-2203. https://doi.org/10.1093/cvr/cvaf180

Vancouver

Jani NR, van Weperen VYH, Ayagama T, Hoang JD, Emamimeybodi M, Bussmann BM, et al. Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn reduce NPY levels via muscarinic receptor activation. Cardiovascular Research. 2025;121(14):2189-2203. doi:10.1093/cvr/cvaf180

BibTeX
@article{Jani2025,
  author = {Jani, Neil R and van Weperen, Valerie Y H and Ayagama, Thamali and Hoang, Jonathan D and Emamimeybodi, Maryam and Bussmann, Benjamin Mothibe and Bal, Sartaj and Kumar, Ashna and Khaky, Artin and Hamon, David and Herring, Neil and Smith, Corey and Vaseghi, Marmar},
  title = {Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn reduce NPY levels via muscarinic receptor activation},
  journal = {Cardiovascular Research},
  year = {2025},
  volume = {121},
  number = {14},
  pages = {2189--2203},
  doi = {10.1093/cvr/cvaf180}
}
Kostenlos starten →